Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Drug Name

Lorbrena® (lorlatinib)

Developer

Pfizer

Therapy Class

Kinase inhibitor

Product Description

Third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor

Current Indication

ALK-positive metastatic non-small cell lung cancer

Market Sector

Oncology

Development Status

Approved in the US and Japan
Expand

Go Top